Skip to main content

Table 1 Baseline characteristics, laboratory parameters, and medication in acute vertigo patients

From: Serum miRNA125a-5p, miR-125b-5p, and miR-433-5p as biomarkers to differentiate between posterior circulation stroke and peripheral vertigo

 

Central Vertigo (n = 23)

Peripheral Vertigo (n = 35)

P value

Age, years, mean (SD)

64.52 (11.80)

63.69 (9.42)

0.766

Female, % (n)

21.7% (5)

82.9% (29)

0.001*

Body mass index, kg/m2, mean (SD)

24.89 (3.96)

24.56 (4.62)

0.59

Onset to blood collection (hrs), mean (SD)

37.59 (16.94)

21.35 (17.91)

0.001*

Stroke risk factors, % (n)

 - Hypertension

65.2% (15)

51.4% (18)

0.30

 - Diabetes mellitus

52.2% (12)

17.1% (6)

0.005*

 - Dyslipidemia

56.5% (13)

48.6% (17)

0.55

 - History of stroke

13.0% (3)

28.6% (10)

0.17

 - History of myocardial infarction

21.7% (5)

2.9% (1)

0.02*

 - Smoking

26.1% (6)

0

0.001*

Previous history of vertigo, % (n)

13% (3)

31.4% (11)

0.11

Systolic BP, mmHg, med (IQR)

161 (146–170)

149 (139–168)

0.10

Diastolic BP, mmHg, med (IQR)

90 (75–100)

80 (68–90)

0.14

Pulse rate, bpm, med (IQR)

80 (60–85)

76 (70–82)

0.87

Laboratory parameters

 - Hemoglobin, g/dL, med (IQR)

13.7 (13.1–15.4)

13.0 (12.5–13.4)

0.009*

 - WBC count, *103/μL, mean (SD)

9.91 (2.95)

8.29 (2.21)

0.03*

 - Platelets, *103/μ, mean (SD)

227.61 (66.43)

266.24 (81.14)

0.07

 - Creatinine, mg/dL, med (IQR)

0.84 (0.71–0.98)

0.67 (0.61–0.82)

0.04*

 - Fasting blood sugar, mg/dL, med (IQR)

130.0 (103–154)

100.0 (80–113.5)

0.008*

 - HbA1C, %, med (IQR)

6.3 (5.6–7.2)

5.6 (5.28–6.2)

0.02*

Medication, n(%)

 - Antiplatelets

17.4% (4)

37.1% (13)

0.11

 - Anticoagulant

0% (0)

2.9% (1)

0.31

  1. WBC white blood cell, LDL low density lipoprotein, HDL high density lipoprotein, SGOT serum glutamic-oxaloacetic transaminase, SGPT serum glutamic pyruvic transaminase, ALP alkaline phosphatase, ACEI angiotensin-converting enzyme inhibitor, ARBs angiotensin II receptor blockers
  2. *P <  0.05